Marshall Wace’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Marshall Wace’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-833	Closed	-$22.5K	–	3116
2023 Q1	$22.5K	Hold	833	–	–	﹤0.01%	2570
2022 Q4	$29.5K	Buy	+833	New	+$100K	﹤0.01%	2859
2022 Q2	–	Sell	-1,144	Closed	-$285K	–	3975
2022 Q1	$285K	Buy	+1,144	New	+$181K	﹤0.01%	2982
2020 Q4	–	Sell	-2,856	Closed	-$698K	–	2268
2020 Q3	$698K	Buy	2,856 +1,079	+61%	+$336K	﹤0.01%	1143
2020 Q2	$512K	Sell	1,777 -1,041	-37%	-$307K	﹤0.01%	1194
2020 Q1	$575K	Buy	+2,818	New	+$898K	0.01%	946
2019 Q4	–	Sell	-177	Closed	-$55K	–	2163
2019 Q3	$55K	Buy	+177	New	+$57.5K	﹤0.01%	1479

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Marshall Wace's EIGR Position: Q2 2023 in Review

Marshall Wace sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2023, closing a stake of 833 shares — an estimated $22.5K sold.

Marshall Wace first reported a position in EIGR in Q3 2019 and held it in 7 quarters. The position peaked at $698K in Q3 2020. 66 funds tracked by Wall St. Rank hold EIGR as of Q2 2023.

Marshall Wace reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Marshall Wace sold 833 Eiger BioPharmaceuticals, Inc. shares in Q2 2023, an estimated $22.5K.
Marshall Wace first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2019 and held it in 7 quarters.
Marshall Wace's Eiger BioPharmaceuticals, Inc. position peaked at $698K in Q3 2020.
66 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2023.

Based on Marshall Wace's 13F filing for Q2 2023, filed 14 Aug 2023.